Company intelligence / Profile preview

Chengdu Yunke Pharmaceutical

Chengdu, Sichuan Sheng/Sichuan Province, Chinacomecer.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Chengdu Yunke Pharmaceutical is a leading Chinese radiopharmaceutical company, the first in China to pass GMP certification for nuclide drugs. Its key products include Iodine‑125 seed sources for tumor brachytherapy and Technetium(99Tc) methylenediphosphonate (Yunke Injection), approved for rheumatoid arthritis and studied in psoriatic arthritis. The company’s clinical results include completed Phase 4 studies and multiple approved products in China.

Therapeutic areas: OncologyRheumatologyImmunology
Modalities: Therapeutic radiopharmaceuticalsSmall molecule
Industry: Biotech

Drug pipeline

2 assets

technetium 99Tc methylene diphosphonate

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chengdu Yunke Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Yunke Pharmaceutical.

Explore the full profile